Researchers at Moffitt Cancer Center have discovered a triple immunotherapy that may shrink tumors in treatment-resistant melanoma. By blocking three key immune checkpoints—PD-1, LAG-3, and TIM-3—this ...

The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy. The low response rates underscore a significant clinical need to ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Mouse PD-1 is significantly weaker than human PD-1, which could have implications for using mice as models in PD-1 studies. Programmed cell death protein 1 (PD-1) has been a key target for cancer ...

A new study from Moffitt Cancer Center brings fresh hope to patients battling advanced melanoma who aren’t helped by today’s best treatments. Researchers have found a powerful combination of three ...